<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03674073</url>
  </required_header>
  <id_info>
    <org_study_id>LKSM001</org_study_id>
    <nct_id>NCT03674073</nct_id>
  </id_info>
  <brief_title>A Study Combining Personalized Neoantigen-based Dendritic Cell Vaccine With Microwave Ablation for the Treatment of Hepatocellular Carcinoma</brief_title>
  <official_title>A Study to Assess the Safety, Feasibility, and Immunogenicity of Personalized Neoantigen-based Dendritic Cell Vaccine in Combination With Microwave Ablation to Treat Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Likang Life Sciences Holdings Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single institution, open-label, multi-arm, pilot study of a personalized
      neoantigen-based dendritic cell (DC) vaccine combined with microwave ablation in subjects
      with Hepatocellular Carcinoma (HCC). Patients with HKLC stage IIa HCC are eligible for
      enrollment. In this study, the investigators are looking at the safety, feasibility of the
      personalized neoantigen-based DC vaccine combined with microwave ablation as well as the T
      cell immune response to the vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2018</start_date>
  <completion_date type="Anticipated">December 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of neoantigen-based DC vaccine as measured by the number of subjects experiencing each type of adverse event according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0.</measure>
    <time_frame>1 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of the neoantigen-based DC vaccine as measured by the frequency of antigen -specific T cells using ELISPOT analysis and ICS analysis.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants alive at 2 years</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival at 2 years</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Liver Cancer, Adult</condition>
  <arm_group>
    <arm_group_label>Microwave Ablation + Neoantigen Vaccines</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The HCC patients will be treated firstly by Microwave Ablation, and then treated by courses of Neoantigen Vaccines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microwave Ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The HCC patients will be treated only by Microwave Ablation.No vaccine will be used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Neoantigen Vaccines</intervention_name>
    <description>HCC (3cm≤D ≤5 cm, fewer than three tumors) patients were treated with Microwave Ablation and 7 courses of neoantigen-based DC vaccines.The first neoantigen-based DC vaccine injection will take place up to 30 days following the completion of Microwave Ablation. The day of the first vaccine injection will be referred to as Day 1.The schedule of vaccination is Day 1, Day 8, Day 15, Day 22, Day 50, Day78, Day106.</description>
    <arm_group_label>Microwave Ablation + Neoantigen Vaccines</arm_group_label>
    <other_name>Personalized Neoantigen-based Dendritic Cell Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microwave Ablation</intervention_name>
    <description>ALL the HCC patients will be treated by Microwave Ablation.</description>
    <arm_group_label>Microwave Ablation</arm_group_label>
    <arm_group_label>Microwave Ablation + Neoantigen Vaccines</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed patients with primary hepatocellular carcinoma, HKLC Stage
             IIa.

          2. Age is greater than 18 years old, male or female.

          3. The tumor size is 3cm-5cm, and the lesions are &lt;3.

          4. ECOG score &lt; 2, Child-Pugh classification A or B.

          5. The participants freely sign informed consent;

        Exclusion Criteria:

          1. Pregnant or breast-feeding; psychiatric problems, addiction, or any other disorder
             that prevented informed consent;

          2. Portal vein thrombosis or extrahepatic metastases;

          3. White blood cell count &lt;2 x 10e9/L, platelet count &lt;40 x 10e9/L, serum creatinine &gt;110
             mol/L, aspartate aminotransferase &gt;3 times upper limit, serum bilirubin &gt; 2.5 times
             upper limit, prothrombin time&gt; 19 seconds.

          4. Active uncontrolled infection;

          5. Concurrent systemic corticosteroid treatment

          6. Primary immunodeficiency or systemic autoimmune disease; being treated with
             immunosuppressive drugs for other diseases;

          7. Clinically significant ischemic heart disease or cardiac failure;

          8. The investigator believes that there are other reasons that are not suitable for
             inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ping Liang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospial</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Yu, Doctor</last_name>
    <phone>8610-66939530</phone>
    <email>yu-jie301@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Chen, Doctor</last_name>
    <phone>8610-84182969-808</phone>
    <email>Chenli@likanglife.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Yu, Doctor</last_name>
      <phone>8610-66939530</phone>
      <email>yu-jie301@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 14, 2018</study_first_submitted>
  <study_first_submitted_qc>September 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2018</study_first_posted>
  <last_update_submitted>October 16, 2018</last_update_submitted>
  <last_update_submitted_qc>October 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Ping Liang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Neoantigen</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Dendritic Cell</keyword>
  <keyword>Personalized</keyword>
  <keyword>Liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

